JP2002355054A - ヘリコバクター・フェリス・ワクチン - Google Patents

ヘリコバクター・フェリス・ワクチン

Info

Publication number: JP2002355054A
Authority: JP; Japan
Prior art keywords: polypeptide; urease; acid sequence; vaccine; nucleic acid
Prior art date: 2000-07-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP2001214711A

Other languages

English (en)

Japanese (ja)

Inventor

Johannes Gerardus Kusters

ヨハネス・ヘラルドウス・クステルス

Giovanni Cattoli

ジヨバンニ・カツトリ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Akzo Nobel NV

Original Assignee

Akzo Nobel NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-17

Filing date

2001-07-16

Publication date

2002-12-10

2001-07-16 Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV

2002-12-10 Publication of JP2002355054A publication Critical patent/JP2002355054A/ja

Status Withdrawn legal-status Critical Current

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 54
241000590017 Helicobacter felis Species 0.000 title claims abstract description 47
229920001184 polypeptide Polymers 0.000 claims abstract description 96
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 96
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 96
108010046334 Urease Proteins 0.000 claims abstract description 69
239000012634 fragment Substances 0.000 claims abstract description 65
150000007523 nucleic acids Chemical group 0.000 claims abstract description 44
108020004414 DNA Proteins 0.000 claims abstract description 39
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 32
208000015181 infectious disease Diseases 0.000 claims abstract description 20
230000000890 antigenic effect Effects 0.000 claims abstract description 12
108020004511 Recombinant DNA Proteins 0.000 claims abstract description 7
238000004519 manufacturing process Methods 0.000 claims abstract description 7
241000282324 Felis Species 0.000 claims abstract description 3
150000001413 amino acids Chemical class 0.000 claims description 42
238000000034 method Methods 0.000 claims description 28
230000002163 immunogen Effects 0.000 claims description 25
241000589989 Helicobacter Species 0.000 claims description 21
241000700605 Viruses Species 0.000 claims description 19
230000028993 immune response Effects 0.000 claims description 15
125000003275 alpha amino acid group Chemical group 0.000 claims description 14
238000002405 diagnostic procedure Methods 0.000 claims description 14
241000282326 Felis catus Species 0.000 claims description 13
238000001514 detection method Methods 0.000 claims description 13
239000002773 nucleotide Substances 0.000 claims description 11
125000003729 nucleotide group Chemical group 0.000 claims description 11
239000002671 adjuvant Substances 0.000 claims description 7
239000000427 antigen Substances 0.000 claims description 7
102000036639 antigens Human genes 0.000 claims description 7
108091007433 antigens Proteins 0.000 claims description 7
244000005700 microbiome Species 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 6
230000001939 inductive effect Effects 0.000 claims description 6
239000000126 substance Substances 0.000 claims description 6
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
102000053602 DNA Human genes 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 4
230000002068 genetic effect Effects 0.000 claims description 4
241000701161 unidentified adenovirus Species 0.000 claims description 4
241000588807 Bordetella Species 0.000 claims description 3
241000125945 Protoparvovirus Species 0.000 claims description 3
230000001717 pathogenic effect Effects 0.000 claims description 3
241000589969 Borreliella burgdorferi Species 0.000 claims description 2
241000282465 Canis Species 0.000 claims description 2
241000606161 Chlamydia Species 0.000 claims description 2
208000000655 Distemper Diseases 0.000 claims description 2
241000713800 Feline immunodeficiency virus Species 0.000 claims description 2
241000711475 Feline infectious peritonitis virus Species 0.000 claims description 2
241000589929 Leptospira interrogans Species 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
206010034674 peritonitis Diseases 0.000 claims description 2
241000726306 Irus Species 0.000 claims 1
241000865120 Okenia felis Species 0.000 claims 1
241000009328 Perro Species 0.000 claims 1
230000036039 immunity Effects 0.000 claims 1
238000003745 diagnosis Methods 0.000 abstract description 2
238000002360 preparation method Methods 0.000 abstract description 2
108091033319 polynucleotide Proteins 0.000 abstract 1
102000040430 polynucleotide Human genes 0.000 abstract 1
239000002157 polynucleotide Substances 0.000 abstract 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 51
229940054541 urex Drugs 0.000 description 51
108090000623 proteins and genes Proteins 0.000 description 38
210000004027 cell Anatomy 0.000 description 22
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 16
239000004202 carbamide Substances 0.000 description 16
241001465754 Metazoa Species 0.000 description 13
239000000523 sample Substances 0.000 description 11
238000002255 vaccination Methods 0.000 description 11
239000000047 product Substances 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 9
239000013598 vector Substances 0.000 description 9
241000894006 Bacteria Species 0.000 description 8
241000282472 Canis lupus familiaris Species 0.000 description 8
230000001580 bacterial effect Effects 0.000 description 8
238000009396 hybridization Methods 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 7
108020004707 nucleic acids Proteins 0.000 description 7
102000039446 nucleic acids Human genes 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
238000012360 testing method Methods 0.000 description 6
108091029795 Intergenic region Proteins 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
230000002496 gastric effect Effects 0.000 description 5
230000003053 immunization Effects 0.000 description 5
230000006698 induction Effects 0.000 description 5
108091026890 Coding region Proteins 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000035772 mutation Effects 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
241000894007 species Species 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
241000590002 Helicobacter pylori Species 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
101150044453 Y gene Proteins 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
229940037467 helicobacter pylori Drugs 0.000 description 3
244000045947 parasite Species 0.000 description 3
238000000746 purification Methods 0.000 description 3
102220201851 rs143406017 Human genes 0.000 description 3
101150030895 ureAB gene Proteins 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
235000014469 Bacillus subtilis Nutrition 0.000 description 2
AYIZHKDZYOSOGY-IUCAKERBSA-N His-Met Chemical compound CSCC[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])CC1=CN=CN1 AYIZHKDZYOSOGY-IUCAKERBSA-N 0.000 description 2
125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 2
108091092724 Noncoding DNA Proteins 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
241000607142 Salmonella Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
101710136524 X polypeptide Proteins 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000010586 diagram Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000003550 marker Substances 0.000 description 2
238000007857 nested PCR Methods 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
230000007170 pathology Effects 0.000 description 2
238000011533 pre-incubation Methods 0.000 description 2
102220240796 rs553605556 Human genes 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
101150061086 ureB gene Proteins 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000001262 western blot Methods 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
241000024188 Andala Species 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
108020000946 Bacterial DNA Proteins 0.000 description 1
208000034309 Bacterial disease carrier Diseases 0.000 description 1
241000606660 Bartonella Species 0.000 description 1
-1 Bayol® or Markol® Substances 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
108010041986 DNA Vaccines Proteins 0.000 description 1
229940021995 DNA vaccine Drugs 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
101100321669 Fagopyrum esculentum FA02 gene Proteins 0.000 description 1
241000701925 Feline parvovirus Species 0.000 description 1
206010056663 Gastric infection Diseases 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
101000835998 Homo sapiens SRA stem-loop-interacting RNA-binding protein, mitochondrial Proteins 0.000 description 1
101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
244000202566 Hydrocotyle vulgaris Species 0.000 description 1
241000588747 Klebsiella pneumoniae Species 0.000 description 1
125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
241000186660 Lactobacillus Species 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108010038049 Mating Factor Proteins 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101710116435 Outer membrane protein Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
102100025491 SRA stem-loop-interacting RNA-binding protein, mitochondrial Human genes 0.000 description 1
102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
239000007875 V-40 Substances 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
102000004139 alpha-Amylases Human genes 0.000 description 1
108090000637 alpha-Amylases Proteins 0.000 description 1
229940024171 alpha-amylase Drugs 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical class [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
101150107976 ey gene Proteins 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
201000011587 gastric lymphoma Diseases 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
229940039696 lactobacillus Drugs 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
108700026241 pX Genes Proteins 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
101150103375 rex gene Proteins 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000003118 sandwich ELISA Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
229940031626 subunit vaccine Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229940124856 vaccine component Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000012130 whole-cell lysate Substances 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

JP2001214711A 2000-07-17 2001-07-16 ヘリコバクター・フェリス・ワクチン Withdrawn JP2002355054A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00202565.8		2000-07-17
EP00202565		2000-07-17

Publications (1)

Publication Number	Publication Date
JP2002355054A true JP2002355054A (ja)	2002-12-10

Family

ID=8171823

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2001214711A Withdrawn JP2002355054A (ja)	2000-07-17	2001-07-16	ヘリコバクター・フェリス・ワクチン

Country Status (10)

Country	Link
US (1)	US7514547B2 (pt)
EP (1)	EP1176192B1 (pt)
JP (1)	JP2002355054A (pt)
AT (1)	ATE251215T1 (pt)
AU (1)	AU782172B2 (pt)
CA (1)	CA2351110A1 (pt)
DE (1)	DE60100879T2 (pt)
DK (1)	DK1176192T3 (pt)
ES (1)	ES2208519T3 (pt)
PT (1)	PT1176192E (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101048181A (zh)	2004-08-13	2007-10-03	巴里·J·马沙尔	细菌递送系统
US8029777B2 (en) *	2004-08-13	2011-10-04	Marshall Barry J	Helicobacter system and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6290962B1 (en) *	1992-11-03	2001-09-18	Oravax, Inc.	Urease-based vaccine and treatment for helicobacter infection
US6258359B1 (en) *	1993-05-19	2001-07-10	Institut Pasteur	Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
JPH08509873A (ja) *	1993-05-19	1996-10-22	アンスティテュ・パストゥール	ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列
US5610060A (en) *	1994-06-24	1997-03-11	The United States Of America As Represented By The Department Of Health And Human Services	Isolated Helicobacter hepaticus
WO1996033220A1 (en) *	1995-04-21	1996-10-24	Csl Limited	Protective helicobacter antigens
JP3007037B2 (ja) *	1995-07-19	2000-02-07	秀実高橋	ヘリコバクター・ピロリ菌ウレアーゼ蛋白由来の人工抗原及びその人工抗原によって誘発された抗体
GB2307987A (en) *	1995-12-06	1997-06-11	Univ Manchester	Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
JP3430853B2 (ja) *	1997-04-11	2003-07-28	株式会社ゲン・コーポレーション	胃炎、胃潰瘍および十二指腸潰瘍の予防剤並びに治療剤
US20030158396A1 (en) *	1997-07-29	2003-08-21	Harold Kleanthous	Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US5985631A (en) *	1997-09-12	1999-11-16	Oravax-Merieux Co.	Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
AU2001258373A1 (en) *	2000-04-27	2001-11-12	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Method for identifying helicobacter antigens

2001
- 2001-07-03 CA CA002351110A patent/CA2351110A1/en not_active Abandoned
- 2001-07-11 PT PT01202666T patent/PT1176192E/pt unknown
- 2001-07-11 DK DK01202666T patent/DK1176192T3/da active
- 2001-07-11 DE DE60100879T patent/DE60100879T2/de not_active Expired - Fee Related
- 2001-07-11 AU AU54321/01A patent/AU782172B2/en not_active Ceased
- 2001-07-11 AT AT01202666T patent/ATE251215T1/de not_active IP Right Cessation
- 2001-07-11 EP EP01202666A patent/EP1176192B1/en not_active Expired - Lifetime
- 2001-07-11 ES ES01202666T patent/ES2208519T3/es not_active Expired - Lifetime
- 2001-07-13 US US09/904,994 patent/US7514547B2/en not_active Expired - Fee Related
- 2001-07-16 JP JP2001214711A patent/JP2002355054A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DK1176192T3 (da)	2004-02-02
AU5432101A (en)	2002-01-24
ATE251215T1 (de)	2003-10-15
PT1176192E (pt)	2004-01-30
US20040005325A1 (en)	2004-01-08
AU782172B2 (en)	2005-07-07
DE60100879D1 (de)	2003-11-06
US7514547B2 (en)	2009-04-07
EP1176192B1 (en)	2003-10-01
EP1176192A3 (en)	2002-02-06
DE60100879T2 (de)	2004-05-19
EP1176192A2 (en)	2002-01-30
ES2208519T3 (es)	2004-06-16
CA2351110A1 (en)	2002-01-17

Publication	Publication Date	Title
EP1928898B1 (en)	2014-08-20	Fish vaccine
EP4410843A1 (en)	2024-08-07	Recombinant fusion protein derived from hr region of s2 protein of sars-cov-2 and application of recombinant fusion protein
US20230167159A1 (en)	2023-06-01	Sars-coronavirus 2 (sars-cov-2) subunit vaccine candidates
JP2003000276A (ja)	2003-01-07	ローソニア・イントラセルラリス・ワクチン
US8025884B2 (en)	2011-09-27	Lawsonia intracellularis subunit vaccines
CN109999191B (zh)	2022-06-24	一种鸡毒支原体新型基因工程亚单位疫苗
CN110256539B (zh)	2020-04-10	O型口蹄疫病毒新型基因工程亚单位疫苗
US9267947B2 (en)	2016-02-23	Compositions and methods for preventing or treating Burkholderia infection
US7201912B2 (en)	2007-04-10	Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis
ES2335668T3 (es)	2010-03-31	Vacuna de sub-unidad de lawsonia intracellularis.
US7279167B2 (en)	2007-10-09	Infectious Salmon Anaemia virus vaccine
US20070212373A1 (en)	2007-09-13	Lawsonia Intracellularis 26 Kd Subunit Vaccine
JP2002355054A (ja)	2002-12-10	ヘリコバクター・フェリス・ワクチン
CN107353329A (zh)	2017-11-17	一种马链球菌兽疫亚种保护性抗原Sec_205及其制备方法
CN112094354A (zh)	2020-12-18	副鸡禽杆菌基因工程亚单位疫苗、其制备方法及应用
AU758555B2 (en)	2003-03-27	Peptides
EP1532253B1 (en)	2014-04-30	Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine
TW201412982A (zh)	2014-04-01	利用生物反應器量產豬鏈球菌之重組表面蛋白抗原及其製造方法與含彼之疫苗組成物
CA2548750A1 (en)	2005-06-23	Lawsonia intracellularis 26 kd subunit vaccine
WO2022246449A1 (en)	2022-11-24	Sars-coronavirus 2 (sars-cov-2) spike protein subunit vaccines
CN107286225A (zh)	2017-10-24	一种马链球菌兽疫亚种保护性抗原map及其制备方法
Cent	1993	Patent Report

Legal Events

Date	Code	Title	Description
2007-02-10	A711	Notification of change in applicant	Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20061222
2008-07-03	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080702
2009-07-23	A761	Written withdrawal of application	Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090722

Date

Code

Title

Description

2007-02-10

A711

Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20061222

2008-07-03

A621

Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080702

2009-07-23

A761

Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090722